J. Deluca

A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma

L. Schwartz, J. Bacik, R. Motzer, 2006, Investigational New Drugs.

Stage migration and increasing proportion of favorable‐prognosis metastatic renal cell carcinoma patients

R. Motzer, N. Ishill, S. Patil, 2010, Cancer.

Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.

M. Bains, J. Bacik, M. Mazumdar, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma

R. Motzer, J. Hsieh, Chung-Han Lee, 2016, The oncologist.

Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma

L. Schwartz, J. Bacik, P. Russo, 2008, Investigational New Drugs.

Phase II Trial of Pegylated Interferon-α2b in Patients with Advanced Renal Cell Carcinoma

L. Schwartz, P. Russo, R. Motzer, 2008 .

Immune markers in adult acute leukemia.

J. Bennett, N. Abramson, J. Deluca, 1976, American journal of clinical pathology.

[791] HCV ANTIVIRAL ACTIVITY AND RESISTANCE ANALYSIS IN CHRONICALLY INFECTED CHIMPANZEES TREATED WITH NS3/4A PROTEASE AND NS5B POLYMERASE INHIBITORS

D. Hazuda, D. Graham, J. Vacca, 2007 .

Pegylated interferon alpha-2B (PEG-Intron) for metastatic renal cell cancer (mRCC): Results of a phase II clinical trial and biologic correlates of response.

L. Schwartz, R. Motzer, J. Bacik, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.